• Mashup Score: 0

    All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.

    Tweet Tweets with this article
    • All patients with metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy. #pcsm #SUO2022 | @UroOnc https://t.co/ep9SgwJ85e

  • Mashup Score: 0
    JELMYTO Virtual Booth - 1 year(s) ago

    JELMYTO by Urogen

    Tweet Tweets with this article
    • Didn't get to witness the innovative technology of @JELMYTO at #SUO2022? Visit the virtual booth for a tangible look inside the innovative technology — and walk through the unique administration process: https://t.co/SCxdn609C9 #Sponsored #Urology https://t.co/WKolCjD1E5